Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Why do we need biosimilars?

Paul Cornes • 21 Mar 2017

Paul Cornes, MD, University Hospital Bristol NHS Foundation Trust, Bristol, UK is one of the UK’s leading experts in biosimilars. Biologic treatments are allowing patients to live longer. Nowadays they can live for many years with some cancers, including chronic blood cancers. Understanding the cost of long-term treatment in cancer, helps us to appreciate how biosimilars could be part of the solution for affordable cancer care.

More from Paul Cornes

4:16
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
Paul Cornes • 22 Jun 2017
2:24
Are biosimilars as efficacious as their reference drugs?
Paul Cornes • 22 Jun 2017
1:21
Explaining biosimilars to our patients
Paul Cornes • 27 Jun 2017
3:56
Can the dream of affordable cancer care come true?
Paul Cornes • 21 Mar 2017
The content of VJHemOnc is intended for healthcare professionals